Teleflex Incorporated (NYSE:TFX) CEO Buys $172,605.00 in Stock

Key Points

• CEO Liam Kelly of Teleflex Incorporated purchased 1,500 shares of the company's stock at an average price of $115.07, increasing his ownership by 3.43% to a total of 45,267 shares.
• Teleflex reported $3.73 EPS for the last quarter, surpassing analyst expectations of $3.36, along with a quarterly revenue of $780.90 million.
• The company declared a quarterly dividend of $0.34 per share, representing a 1.2% dividend yield, with the payment scheduled for September 15th.

Teleflex Incorporated (NYSE:TFX - Get Free Report) CEO Liam Kelly acquired 1,500 shares of the business's stock in a transaction on Tuesday, August 5th. The shares were purchased at an average price of $115.07 per share, for a total transaction of $172,605.00. Following the transaction, the chief executive officer directly owned 45,267 shares of the company's stock, valued at approximately $5,208,873.69. The trade was a 3.43% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Teleflex Price Performance

TFX stock traded down $0.85 during mid-day trading on Monday, reaching $117.57. 16,693 shares of the company's stock were exchanged, compared to its average volume of 801,558. The company has a market cap of $5.20 billion, a price-to-earnings ratio of 27.83, a price-to-earnings-growth ratio of 1.65 and a beta of 1.08. The stock's 50 day moving average is $118.09 and its 200 day moving average is $134.28. Teleflex Incorporated has a 12-month low of $108.90 and a 12-month high of $249.90. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44.

Teleflex (NYSE:TFX - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.36 by $0.37. Teleflex had a return on equity of 15.08% and a net margin of 6.31%. The business had revenue of $780.90 million for the quarter, compared to analysts' expectations of $771.53 million. During the same quarter in the prior year, the firm posted $3.42 EPS. The company's revenue was up 4.2% compared to the same quarter last year. On average, research analysts expect that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Stockholders of record on Friday, August 15th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Friday, August 15th. Teleflex's dividend payout ratio (DPR) is currently 32.00%.

Institutional Investors Weigh In On Teleflex

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Teleflex by 0.4% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 20,320 shares of the medical technology company's stock valued at $3,614,000 after buying an additional 74 shares during the period. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Teleflex by 103.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock valued at $27,000 after buying an additional 100 shares during the last quarter. Thompson Investment Management Inc. grew its stake in Teleflex by 2.1% during the 2nd quarter. Thompson Investment Management Inc. now owns 4,970 shares of the medical technology company's stock valued at $588,000 after acquiring an additional 100 shares in the last quarter. True Wealth Design LLC boosted its position in shares of Teleflex by 62.3% during the 4th quarter. True Wealth Design LLC now owns 271 shares of the medical technology company's stock worth $48,000 after purchasing an additional 104 shares during the period. Finally, CX Institutional grew its position in shares of Teleflex by 14.7% in the 2nd quarter. CX Institutional now owns 872 shares of the medical technology company's stock valued at $103,000 after buying an additional 112 shares during the last quarter. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently commented on TFX. Wall Street Zen raised Teleflex from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 2nd. Morgan Stanley decreased their price target on Teleflex from $191.00 to $173.00 and set an "overweight" rating for the company in a research note on Monday, May 5th. Mizuho raised their price target on Teleflex from $130.00 to $135.00 and gave the company a "neutral" rating in a report on Friday, August 1st. Wells Fargo & Company lowered their target price on Teleflex from $137.00 to $131.00 and set an "equal weight" rating on the stock in a research report on Friday, August 1st. Finally, Truist Financial decreased their price target on Teleflex from $140.00 to $137.00 and set a "hold" rating for the company in a report on Monday, May 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $141.57.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.